> top > projects > ASCO_abstracts > docs
ASCO_abstracts  

Documents (3,155) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
asco@alo33 162026 Background: Trastuzumab plus chemotherapy is the treatment of choice for locally advanced or metastatic gastric cancer patients. Pathological assessment of gastric cancer specimens hoever still rema 2.18 KB 2023-01-16 1 2023-01-16
asco@alo33 162032 Background: We investigated the activity and safety of RE in doxorubicin-pretreated metastatic soft tissue sarcomas STS . Methods: REGOSARC NCT01900743 consisted of 4 independent cohorts of patie 2.26 KB 2023-01-16 1 2023-01-16
asco@alo33 162036 Background: In 2013, based on the Bureau of Justices latest statistics, 90 percent of deaths in state prisons ere illness-related, 31 percent of these ere due to cancer CA folloed by heart disease 2.4 KB 2023-01-16 1 2023-01-16
asco@alo33 162045 Background: Anthracyclines are an important component of multiple drug chemotherapy regimens used in the treatment of osteosarcoma OGS . Limited data exists regarding early chronic anthracycline in 2.25 KB 2023-01-16 1 2023-01-16
asco@alo33 162052 Background: The clinical behavior of patients ith advanced non-small cell lung cancer NSCLC differ beteen epidermal groth factor receptor EGFR exon 19 deletion Ex19 and EGFR exon 21 L858R muta 1.82 KB 2023-01-16 1 2023-01-16
asco@alo33 162064 Background: Although oral metronomic chemotherapy is often used in progressive paediatric solid malignancies in the palliative setting, its usage is notable for scepticism and empiricism.Literature 2.33 KB 2023-01-16 1 2023-01-16
asco@alo33 162068 Background: Bevacizumab BV as approved in February 2010 in China ith indication of combined ith 5-FU for metastatic colorectal cancer mCRC . Post-marketing surveillance of patients Pts ho recei 2.43 KB 2023-01-16 1 2023-01-16
asco@alo33 162078 Background: Volumetric parameters of positron emission tomography-computed tomography using 18F-fludeoxyglucose 18F-FDG PETCT that comprehensively reflect both metabolic activity and tumor burden 1.89 KB 2023-01-16 1 2023-01-16
asco@alo33 162080 Background: MPACT study shoed survival benefit of nab-gem vs. gem in APC [Von Hoff D, NEJM 2013]. Sensory peripheral neuropathy is a dose-limiting toxicity associated ith nab. Neuromodulatory agents 2.3 KB 2023-01-16 1 2023-01-16
asco@alo33 162083 Background: The presence of portal vein tumor thrombosis PVTT in patients ith hepatocellular carcinoma HCC is regarded as indicating an advanced stage, and liver resection LR is not recommende 1.83 KB 2023-01-16 1 2023-01-16